Affiliation:
1. Endocrinology Research Centre
2. V.A. Almazov National Medical Research Center
3. I.M. Sechenov First Moscow State Medical University (Sechenov University)
4. Pirogov Russian National Research Medical University
5. Moscow State University of Medicine and Dentistry named after A.I. Evdokimova
6. Novosibirsk State Medical University
7. Tyumen State Medical University
Abstract
Over the past 10 years of studying the complications of type 2 diabetes mellitus (DM) and ways to deal with them, significant progress has been made in one of the most important areas of treatment — the prevention of cardiovascular and renal complications. Thus, when using inhibitors of type 2 sodium-glucose cotransporter, a significant reduction in the risks of cardiovascular mortality and progression of chronic heart failure, which occupy the main place in the structure of mortality in this cohort of patients, as well as a positive effect on diabetic nephropathy, one of the most common complications of type 2 diabetes, has been proven. However, there are other complications that significantly affect the duration and quality of life of patients. In particular, these include stroke, which occupies the 2nd-3rd place in the frequency of death of people with type 2 diabetes, and albuminuria, a frequent manifestation of diabetic kidney disease, which is associated with an increased risk of cardiovascular complications (including stroke) and chronic renal failure. Recent studies indicate the important role of sodium-glucose cotransporter type 1 in the development of these complications. Canagliflozin has the highest affinity for these transporters among iSGLT-2 registered in the Russian Federation. This article aims to evaluate the mechanisms of action of canagliflozin and its possible role in the prevention of stroke and albuminuria.
Publisher
Endocrinology Research Centre
Subject
Endocrinology,Endocrinology, Diabetes and Metabolism,Internal Medicine
Reference49 articles.
1. Gregg EW, Menke A. Diabetes and Disability. In: Diabetes in America 3rd edition. National Institute of Diabetes and Digestive and Kidney Diseases (US); 2018.
2. Dedov II, Shestakova MV, Vikulova OK, et al.Epidemiological characteristics of diabetes mellitus in the Russian Federation: clinical and statistical analysis according to the Federal diabetes register data of 01.01.2021. Diabetes mellitus. 2021;24(3):204-221. (In Russ.). doi: https://doi.org/10.14341/DM12759
3. Yau K, Dharia A, Alrowiyti I, et al. Prescribing SGLT2 Inhibitors in patients with CKD: Expanding indications and practical considerations. Kidney Int Rep. 2022;7(7):1463-1476. doi: https://doi.org/10.1016/j.ekir.2022.04.094
4. Cardoso R, Graffunder FP, Ternes CMP, et al. SGLT2 inhibitors decrease cardiovascular death and heart failure hospitalizations in patients with heart failure: A systematic review and meta-analysis. EClinicalMedicine. 2021;(36):100933. doi: https://doi.org/10.1016/j.eclinm.2021.100933
5. Данные Федерального регистра сахарного диабета Московской области [дата обращения: 01.07.2023]. [Data of the Federal Register of Diabetes Mellitus of the Moscow Region [date of access: 07/01/2023] (In Russ.)]